Oral Dispersible Tablets Research Articles

Application of Stability-indicating RP-HPLC Method for quantification of Ticagrelor In Oral dispersible tablet dosage form

Application of Stability-indicating RP-HPLC Method for quantification of Ticagrelor In Oral dispersible tablet dosage form

Formulation Development and Evaluation of Ticagrelor Oral Dispersible Tablets by Using Co-processed Superdisintegrants

Ticagrelor is a contemporary anti-platelet drug that inhibits the aggregation of platelets by blocking the adenosine phosphate (ADP) receptors of the subtype P2Y12; generally utilized in patients who have a previous history of myocardial infarction or with acute coronary syndrome to prevent occurring of myocardial infarction, cardiovascular death and stroke in future. This study focuses on the development of formulation development & assessment of an oral dispersible tablet of ticagrelor, a Biopharmaceutical Classification System (BCS) class 4 drug, by using the co-processed superdisintegrants to enhance drug dissolution and bioavailability. Wet granules with different concentrations of co-processed superdisintegrants developed the tablets. This study includes seven formulations that were formulated using the different selected excipients. The various batches were assessed for physical characteristics, disintegration, dissolution studies, hardness and friability. In-vitro dissolution investigations were conducted for formulations. S1 to S7 at time points 5, 15 and 30 minutes. According to the results of the formulation S7 was discovered to be the optimum formulation, as shown 102.89% drug release at 5 minutes and a disintegration time of 16 seconds. Thus, it appears that S7 is the most suitable formulation of ticagrelor oral dispersible tablet in order for enhanced bioavailability.

Review of Oral Tablet

Abstract: Oral drug delivery is noninvasive, has a high rate of patient compliance, is easy to handle, and doesn't require any special sterile settings, it is the most popular method of administration. Nevertheless, a number of physical, biological, and pharmacological obstacles that certain medications must overcome in order to be absorbed into the systemic circulation reduce their therapeutic efficiency. The use of nanocarriers to deliver drugs orally has proven to be an effective solution to the aforementioned problems and is being explored as a potential replacement for oral medication administration. This chapter provides an overview of the latest developments in the use of nanocarriers for oral medication delivery in the treatment of different disorders. The chapter also describes how diverse nanocarrier designs and technologies improve therapeutic potential by overcoming physical, biological, and biochemical obstacles. it is easy to produce, has few sterility limitations, is less expensive, has flexible dosage form design, and has high patient compliance, oral drug delivery (ODD) is the most convenient and favored method of drug administration. However, low medication bioavailability—which is influenced by three crucial factors—is one of the difficulties associated with oral drug delivery. The other is solubility. Many mathematical models that predict the medication's rate of solubility and dissolution have been developed in order to achieve efficient drug absorption in vivo. Similarly, models that are noncellular and cellular determine permeability. Furthermore, the medication's behavior in the gastrointestinal tract (GIT) is influenced by physiological parameters, such as pH, microbial colonization, and enzymes, as well as intrinsic drug properties. A drug's dosage form is a method of getting it into a living organism. The medicine must be administered to the site of action at a rate and concentration that will maximize therapeutic benefit and minimize side effects in order to provide the intended result. Although the oral method is still commonly used, swallowing tablets and capsules can be a regular problem. As a result, numerous studies on cutting-edge drug delivery methods have been conducted. This review focuses on oral dispersible tablets, a novel approach to drug delivery systems that are currently more focused on formulation and set a new course that not only helped patients increase their level of therapy compliance.

Cellulose nanocrystals as an innovative superdisintegrant for oral dispersible tablets

Oral Dispersible Tablets (ODTs), designed for rapid disintegration in the oral cavity, offer advantages such as easy administration for diverse populations and faster drug absorption. Microcrystalline cellulose (MCC) has been a traditional choice as a disintegrant, but its limitations have led to increased interest in cellulose nanocrystals (CNCs). This study focuses on obtaining and characterizing CNCs derived from MCC by sulfuric acid hydrolysis, exploring different times and drying methods (lyophilization or spray drying). At a 50 % v/v acid concentration for 60 min at 45 °C it was possible to extract CNC with a 76 % yield. When lyophilized, CNC micrographs showed large aggregates with few isolated particles, while the spray-dried samples were seen as free, elongated particles. The resulting CNCs, with enhanced properties like high hydrophilicity and surface area, are investigated for their impact on ODT formulations. All of them disintegrated faster than 10 s. A comprehensive analysis of ODTs' disintegration mechanism was also undertaken. The drying method dictates the predominant disintegration mechanism, even though this is also influenced by the nanoparticle size. Therefore, the study contributes insights into the potential of CNCs as innovative superdisintegrants, offering a promising path for improving oral drug delivery systems.

Formulation and Evaluation of Oral Dispersible Tablet of Poorly Water-Soluble Drug ‘Glimepiride’ by Using Solubility Enhancement Technique

The present study is regarding Glimepiride (GMP) is poorly water-soluble drug. According to the BCS, Glimepiride undergoes Class II - High Permeability and Low Solubility. The objective of the research project is to enhance the solubility of Glimepiride by using solubility enhancement techniques. The endeavor is to improve its solubility by using super disintegrating agent to enhance the ability of disintegration of Oro dispersible tablet. To enhance of solubility of GMP, our select the method i.e. solid dispersion technique because Solid dispersion is an effective way of improving the dissolution rate of poorly water-soluble drugs and hence its bioavailability. The polymers used were PEG 4000 and PEG 6000 for prepared solid dispersions in different ratio by two method i.e. Fusion and solvent evaporation method. The solvent evaporation method is better result of drug for enhancement of solubility. Oral dispersible tablet of Glimepiride was prepared by direct compression method. ODTs of glimepiride by using different super disintegrants such as sodium starch glycolate, cross povidone and croscarmellose sodium. Further, post evaluation parameters like Shape and Color of Tablets, Thickness, hardness, friability, weight variation, Uniformity of Drug Content, In vitro Dissolution Rate Studies and In-vitro disintegration time were also evaluated and the results were discussed.

Oral Dispersible Tablet: A Review

Demand for ODT is increasing day by day particularly in pediatric, geriatric and patients with some sort of disabilities in swallowing. ODTs are those tablets which gets rapidly dissolved in saliva. They do not need water for administration. Oral dispersible tablets are also known as fast melting tablets. The current article reviews the introduction, ideal characteristics, advantages and disadvantages, limitations, challenges in formulating ODTs, formulations of ODTs, technologies used in ODTs, selection of superdisintegrants and evaluation methods.

Formulation and evaluation of oral dispersible tablet of nimesulide by direct compression method

Based on Biopharmaceutics Classification System (BCS), nimesulide is a class II drug, characterized by low solubility and high permeability. Thus, its dissolution represents a limiting step in the drug absorption process which directly affects the bioavailability of the drug. Oral Dispersible tablets (ODTs) of nimesulide overcome the problem related to dissolution by enhancing the rate of dissolution by decreasing the disintegration time and making it easy to administer to patients who refuse to swallow a tablet. In the present study, different formulations of nimesulide were prepared to vary the concentration of superdisintegrants: crospovidone, croscarmellose sodium, sodium starch glycolate along with other excipients: PVP K-30, Aerosil, Mannitol, and Magnesium stearate by direct compression method. Precompression and post-compression parameters were evaluated and also the effect of different concentrations of superdisintegrants on the release profile of Nimesulide ODT was studied. The final data revealed that a combination of 10% crospovidone and 8.33% SSG i.e. formulation B4 was found best combination with the lowest dispersion time of 40 seconds, lowest disintegration time of 19.16 seconds, and lowest wetting time of 15 seconds as compared to other formulations. All other studied parameters were found to be satisfactory for all ODT formulations for Nimesulide. It was concluded that Nimesulide can be successfully formulated as oral dispersible tablets using various superdisintegrants in different concentrations by direct compression method. The optimized batch can be subjected to real-time and accelerated stability studies to determine the shelf life for commercial use.

A Review on Orodispersible tablet

The oral route is the most important and recommended route of drug administration. Oral route is the safest and convenient route of drug delivery because of wide range of drugs are administered through this route. Oro dispersible tablets are novel oral drug-delivery system as they have improved patient compliance and have some additional advantages compared to other oral formulation. Oral dispersible tablet are solid unit dosage forms, which disintegrate or dissolves quickly in the mouth within a minute in the presence of saliva without chewing or water. The dosage form containing super disintegrates which impart the quality of quick disintegration in the presence of saliva and also play an important role in the formulation of oral dispersible tablets. The present review is focused on ideal properties, objective, advantages and disadvantages and evaluation parameters.

TASTE MASKED CLOPERASTINE HYDROCHLORIDE AND RUPATADINE ORAL DISPERSIBLE TABLETS: FORMULATION DESIGN, DEVELOPMENT, CHARACTERIZATION AND PHARMACOKINETICS STUDY ON WISTAR RATS

Objective: The main objective of our study was formulating oral dispersible tablets (ODTs) of taste masked cloperastine HCl and rupatadine fumarate by using the lyophilization technique that also enhanced the dissolution of poor solubility of these active substances. Methods: Taking 3 super disintegrants as variables using the Minitab® 18 factorial design method, 27 formulae of ODTs were obtained. The powdered mixtures before direct compression were characterized using Carr’s index, Hausner’s ratio, and angle of repose. The best-powdered formulae were elected to be prepared as ODTs by direct compression to undergo characterization tests such as wetting time, in vitro disintegration test, and in vivo taste masking. According to the Quality by Design QbD approach; the best formula of ODTs prepared by direct compression was elected to be optimized by the lyophilization technique. Incorporating Eudragit E PO®has a major role in the taste masking of lyophilized ODTs. A comparative in vivo pharmacokinetic study of market products of two active substances was carried out for the conventional ODTs, lyophilized tablets, and market products using wistar rats by oral administration of (0.75 mg/ml) for each active substance. Results: The bitter taste was apparently masked in the lyophilized ODTs assessed by in vivo taste masking. The highest Cmax of cloperastine HCl was found at 17.25 mcg/ml in the group of Lyophilized ODTs. Furthermore; the highest Cmax of rupatadine was found at 78.88 mcg/ml in the same group. Conclusion: Lyophilized tablets owned the best bioavailability for both active substances with the highest Cmax compared to market products and ODTs prepared by direct compression.

Formulation and Characterization of Oral Dispersible Tablet of Aprepitant

The oral route of drug administration is more common and convenient where tablets and capsules emerged as popular dosage form but many patients have dysphasia or difficulty in swallowing which is currently affecting 35% general population. Aprepitant is anti-emetic drug and used in the treatment of chemotherapy in cancer. Fast onset of action is required in this indication there for it was thought to prepare Oral Dispersible Tablet of Aprepitant which would help to avoid first pass metabolism and improve bioavailability also Aprepitant is insoluble in water so, to increase the solubility solid dispersion method (kneading method) was used. Here, Aprepitant ODT is prepared by direct compression method using Polyplasdone XL10 as superdisitegrant and optimized by 32 Full factorial design. Here, Polyplasdone XL10 (x1) and Mannitol(x2) is use as independent variable. while dependent variable are disintegration time and wetting time. Optimized formulation F8 batch showed drug content (98.41±0.91); disintegration time is (18.02±1.20) Wetting time (22.53±0.43). The formulation is stable at 40ºc/75% RH for 30days.

A REVIEW ON: FORMULATION, TECHNOLOGICAL AND BENEFICIAL ASPECTS OF ORAL DISPERSIBLE TABLETS

This review is about oral dispersible tablets a novel approach in drug delivery systems that are now a day’s more focused in formulation world, and laid a new path that, helped the patients to build their compliance level with the therapy, also reduced the cost and ease the administration especially in case of pediatrics and geriatrics. Oral dispersible tablets are advantageous for pediatric, geriatric mentally ill, nausea patients who have difficulty in swallowing conventional tablets and capsules. Using various excipients, evaluation tests marketed formulation and drugs used in the research area. The advantages of mouth dissolving dosage form are increasingly being recognized in both, industry and academia. Their growing importance has been underlined recently when European Pharmacopoeia adopted the term “Oral dispersible Tablet” as tablet that is to be place in the mouth where it disperses rapidly before swallowing. When ODTs are put on tongue they disintegrate instantaneously, releasing the drug which dissolve or disperses in the saliva. Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes down in to the stomach. In such cases, bioavailability of a drug is significantly greater than those observed from conventional tablet dosage form.

DESIGN AND IN VITRO EVALUATION OF ACRIVASTINE AS ORODISPERSIBLE TABLET USING DIRECT COMPRESSION METHOD.

The aim: This study aimed to develop mouth-dissolving tablets of Acrivastine, an antihistamine medication, in order to increase its oral bioavailability. Materials and methods: Different super disintegrants, such as crospovidone, croscarmellose sodium, and sodium starch glycolate, were used to make Acrivastine oral dispersible tablets (ODTs). These super disintegrants were utilized in various concentrations. The formulation (F3) with 6% w/w crospovidone had a fast disintegration time (less than 30 seconds) and practically total drug release within 10 minutes. All of the formulations were made using the direct compression method and proper diluents, binders, and lubricants. Fourier transform infrared spectroscopy (FTIR) tests were used to investigate the drug-ex¬cipient interaction, and all formulations demonstrated improved drug-excipient compatibility. Results: The average weight of all formulations was between 175 and 180 mg. All formulations' hardness and friability were within acceptable ranges. Direct compression tablets had a hardness of 3.2 to 4 kg/cm2. All formulations were determined to have a friability of less than 1.0%. For oral dissolving tablets, the in vitro disintegration time is critical, and this time preferred to be < 60 seconds. The results also showed that crospovidone disintegrated after 24 seconds and sodium starch glycolate disintegrated in 40 seconds in vitro. Conclusions: When compared to croscarmellose sodium and sodium starch glycolate, crospovidone performs better as a super disintegrant. In comparison to other formula, tablets breakdown in the mouth in 30 seconds and have a maximum in vitro drug release time in 1-3 minutes.

Effectiveness, safety and adherence to therapy with Elicea Q-Tab in real clinical practice

To evaluate the effectiveness and safety of escitalopram in the form of oral dispersible tablets (Elicea Q-Tab) in real-life clinical practice in patients with depressive and anxiety disorders. The study included 1.892 outpatient patients, 1.860 of whom completed participation in accordance with the protocol and entered the statistical analysis. Most patients were diagnosed with depressive and anxiety disorders of varying severity, as a rule, these diagnoses were established for the first time. The drug was most often prescribed at a dosage of 10 mg/day. The patients were monitored for 90 days and at each of the 3 visits, scales were used to assess the clinical condition (CGI-S and CGI-I), scales «Interaction with people, maintaining relationships (social functioning)» and «Availability of work, task completion, school attendance (professional functioning)», scales satisfaction with the convenience of admission/appointment and the effectiveness of treatment, various indicators of quality of life (autonomy, social and professional functioning, hobbies and hobbies), as well as the severity of cognitive disorders were measured. Patients treated with escitalopram in the form of oral tablets dispersible in the oral cavity (Elicea Q-Tab) showed an improvement in their clinical condition (a decrease in CGI-S scores from 3.65 at visit 1 to 2.63 by visit 3, by 28%; a decrease in CGI-I scores from 2.39 at visit 1 to 1.57 to visit 3, by 34%), as well as improving the quality of life, social (from 2.74 points on 1 visit to 4.32 on 2 visits, by 58%) and professional functioning (from 2.81 on 1 visit to 4.35 on 2 visits, by 55%), the level of concentration (from 3.28 points on 1 visit up to 4.5 on 3 visits, by 37%). Doctors and patients noted high satisfaction with the effectiveness and convenience of using the drug, the frequency of adverse events was low. The study showed that escitalopram in the form of oral tablets dispersible in the oral cavity (Elicea Q-Tab) is an efficient and safe treatment for depressive and anxiety disorders in real-world clinical settings. Patients and physicians have evaluated the drug positively and it can be considered as an effective agent in psychiatric practice.

Formulation Development and Evaluation of Oro-Dispersible Tablets Based On Solid Dispersion of Cimetidine

The most common problem about conventional dosage form is dysphagia (difficulty in swallowing). So, we design a new approach in a conventional dosage form which is oral dispersible tablet. Oral dispersible tablet is also called as mouth dissolving tablet, fast dissolving tablet, or oral disintegrating tablet. Oral dispersible tablet has advantage as it quickly disintegrates into saliva when it is put on the tongue. The faster the drug disintegrates or is dissolved, the faster the absorption and the quicker the therapeutic effect of drug will be attained. The objective of present study was to formulate directly compressible orodispersible tablets of cimetidine with improved solubility and bioavailability by using solid dispersion technique. Cimetidine is a histamine H2-receptor antagonist. It is widely prescribed in active duodenal ulcers, gastric ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease and erosive esophagitis. Solid dispersion of cimetidine was prepared by anti-solvent addition method and physical mixture using novel polymer eudragit E 100. Saturation solubility of drug was determined in physical mixture and solid dispersion formulation. The prepared solid dispersion formulations were further characterized by drug contents, HPLC, and encapsulation efficiency. Orodispersible tablets of cimetidine were prepared by direct compression method and blend was evaluated for the pre-compression parameters such as bulk density, compressibility, angle of repose etc. The tablets were prepared by using selected solid dispersion formulation and excipients with sodium starch glycolate as a superdisintegrant and evaluated for hardness, friability, weight variation, content uniformity, wetting time, dispersion time and in-vitro drug release. Orodispersible tablet shows wetting time 27±1 seconds and in-vitro drug release 93.20±3.181%, which is better as compare to tablet containing pure drug (82.36±1.986) within 20min. Thus formulation of orodispersible tablet of cimetidine solid dispersion showed increased solubility and bioavailability with patient complies and convenience.&#x0D; Keywords: Cimetidine, Orodispersible tablets, Solid dispersion, Anti solvent addition method, Superdisintegrant

Development of Orodispersible Ibuprofen Tablets Based on a Polymer-drug Complex

Introduction. Orodispersible dosage forms are a very promising direction in the development of dosage forms. Such dosage forms are designed for both systemic and local action of the active pharmaceutical ingredients that make up their composition. Active pharmaceutical ingredients from orodispersible forms enter directly into the systemic circulation, bypassing the "first pass effect".Aim. Development of orodispersible tablets based on the Eudragit® EPO/ibuprofen polymer-drug complex and evaluation of ibuprofen release from the resulting system.Materials and methods. Samples of the polymer-drug complex (PDC) were obtained with different ratios of EPO and ibuprofen, as well as with different mixing orders. Turbidimetric studies to find the stoichiometry of the resulting EPO/IB PLC were performed spectrophotometrically (Lambda 25, PerkinElmer, U.S.A.) at a wavelength of 600 nm. Thermal analysis was performed by modulation differential scanning calorimetry (mDSC) on a Discovery™ DSC instrument (TA Instruments, U.S.A.). Samples sealed in Tzero aluminum pans (TA Instruments, U.S.A.) were scanned in the temperature range from 0 to 250 °С at a speed of 2 °С/min. IR spectra were recorded on a Nicolet iS5 FT-IR spectrometer (Thermo Fisher Scientific, U.S.A.) with an ATR nozzle, in the range from 500 to 4000 cm-1. Drying of samples of complexes and dispersible tablets was carried out in a FreeZone 1L laboratory freeze dryer (Labconco, U.S.A.) for a 24 hours at a temperature of –49 °C and at a pressure of 0.350 mbar. The drug release was evaluated on a dissolution tester DT 828 (ERWEKA GmbH, Germany) in a volume of 900 ml, at 37 ± 0.5 °C and a blade rotation speed of 50 rpm.Results and discussion. Studies on the formation of PDC Eudragit® EPO/ibuprofen (EPO/IB) were carried out at various molar ratios. On samples of PDC and individual components, bands are observed that are characteristic both for EPO – at 2770 and 2820 cm-1, confirming the presence of non-ionized dimethylamino groups, and at 1725 cm-1, corresponding to the stretching vibrations of carboxyl groups. A new band is appeared at 1573 cm-1, which confirm the formation of ionic bonds between carboxylate groups of IB and ionized dimethylamino groups of EPO. The mDSC thermograms of the samples are characterized by a single glass transition temperature (Tg) at 27,3 ± 0,3 °С (for molar ratio 1 : 2) and 44,9 ± 0,4 °С. (for molar ratio 1 : 1), which confirm the formation of polymer-drug complexes. Received PDC Eudragit® EPO/ibuprofen in a molar ratio of 1 : 2 and 1 : 1 and oral dispersible tablets based on them by lyophilization. The resulting systems are characterized by immediate release of IB with maximum rates at 30 min for a 1 : 1 composition and 60 min for a 1 : 2 composition.Conclusion. Eudragit® EPO/ibuprofen polymer drug complex can be used to develop orodispersible tablets providing immediate release of IB.

Formulation and evaluation of serratiopeptidase and salbutamol tablet for dysphagia

Oral Dispersible Tablet of Serratiopeptidase and salbutamol were prepared, evaluated and different types of concentration and dissolution of tablets were studied. In FTIR, drug and excipients with their mixture showed that there is no interaction between the drug molecule and excipients used. The Percentage of drug content of tablets in the formulations was found to be 95 % to 105% which complies with the limits of pharmacopoeia. By the process of direct compression method was used to prepare oral Dispersible tablet containing 300 mg of Serratiopeptidase and salbutamol. formulation was conducted using different concentrations of croscarmellose, micro crystalline cellulose, as a super disintegrants. And their interaction with Serratiopeptidase and salbutamol also evaluated using FTIR.

Formulation and Evaluation of Chewable Oral Jelly containing Zolmitriptan hydrochloride

The present study aimed to develop an immediate release of Zolmitriptan hydrochloride oral jellies for the treatment of severe migraine. The jellies were prepared by using chitosan hydrochloride with different concentration as a polymer and propylene glycol as a co-polymer. The prepared jellies were evaluated for its various physio-chemical parameters such as pH, appearance, viscosity, in vitro drug release and drug content. The pH of the prepared formulations was found to be in the range of 7.5-8.1. The appearance of the prepared formulations was transparent to opaque. The viscosity of the prepared jellies was found to be in the range of 273600 - 542335 CPS. The drug content of the prepared jellies was found to be more than 97%. The in vitro drug release immediate release with increased concentration of Chitosan Hydrochloride, and the drug release were found to be more than 60% in 15 minutes. This present studies concluded that Zolmitriptan hydrochloride oral jellies can be a better alternative for oral dispersible tablets and it could produce improved bioavailability as compared to other fast releasing dosage form. From the above studies of various parameters, it was concluded that the FJ5 formulation was found to be optimized formulation.

Puzzle out Machine Learning Model-Explaining Disintegration Process in ODTs.

Tablets are the most common dosage form of pharmaceutical products. While tablets represent the majority of marketed pharmaceutical products, there remain a significant number of patients who find it difficult to swallow conventional tablets. Such difficulties lead to reduced patient compliance. Orally disintegrating tablets (ODT), sometimes called oral dispersible tablets, are the dosage form of choice for patients with swallowing difficulties. ODTs are defined as a solid dosage form for rapid disintegration prior to swallowing. The disintegration time, therefore, is one of the most important and optimizable critical quality attributes (CQAs) for ODTs. Current strategies to optimize ODT disintegration times are based on a conventional trial-and-error method whereby a small number of samples are used as proxies for the compliance of whole batches. We present an alternative machine learning approach to optimize the disintegration time based on a wide variety of machine learning (ML) models through the H2O AutoML platform. ML models are presented with inputs from a database originally presented by Han et al., which was enhanced and curated to include chemical descriptors representing active pharmaceutical ingredient (API) characteristics. A deep learning model with a 10-fold cross-validation NRMSE of 8.1% and an R2 of 0.84 was obtained. The critical parameters influencing the disintegration of the directly compressed ODTs were ascertained using the SHAP method to explain ML model predictions. A reusable, open-source tool, the ODT calculator, is now available at Heroku platform.

Oral Dispersible Tablets of GK-2 [bis-(N-Monosuccinyl-L-Glutamyl-L-Lysine) Hexamethyleneamide]: Optimization of Pressing Process by Mathematical Modeling Based on the Heckel and Kawakita Equations

Oral Dispersible Tablets of GK-2 [bis-(N-Monosuccinyl-L-Glutamyl-L-Lysine) Hexamethyleneamide]: Optimization of Pressing Process by Mathematical Modeling Based on the Heckel and Kawakita Equations

Formulation and Evaluation of Oral dispersible Tablet of Paroxetine Hydrochloride

Orodispersible tablets (ODTs) is one such novel approach which helps to increase user acceptance by virtue of rapid disintegration, self-administration without water or chewing. ODTs are solid unit dosage forms like the conventional tablets containing super disintegrants, which help them to disintegrate and/or disperse rapidly in the mouth within few seconds. The orodispersible tablet of Paroxetine hydrochloride was prepared by using direct compression method and the tablet were formulated using various concentration of Kyron T-314 as disintegrating agent, PVP K-30 as binder, F melt Type C as diluent, Sodium Saccharin as sweetening agent, talc as lubricant and Aerosil as glidant respectively. All the batches were prepared according to Factorial design. The prepared tablets were evaluated for various parameters like hardness, dissolution, friability, weight variation, disintegration time. Batch F5 was found to be the best batch as the disintegration time is minimum (26seconds) and better drug release profile. Orodispersible tablets of Paroxetine Hydrochloride were successfully formulated by which first pass metabolism could be avoided and faster onset of action could be achieved.